The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York September 17, 2020. — Reuters pic
REGEN-COV — featuring potent neutralizing antibodies called imdevimab and casirivimab — remained effective against both variants, the company said in a statement, although casirivimab’s potency against the South African variant was “reduced.” “These data show the continued ability of REGEN-COV to neutralize emerging strains, further validating our multi-antibody cocktail approach to infectious diseases,” said George Yancopoulos, Regeneron’s president and chief scientific officer.
เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม: